Microencapsulation of genetically engineered cells may have important applications as delivery systems for therapeutic proteins. However, optimization of the microcapsules with regard to mechanical stability, cell growth, and secretion of proteins is necessary in order to evaluate the future use of this delivery technology. We have explored the growth, survival, and secretion of therapeutic proteins from 293-EBNA cells producing endostatin (293 endo cells) and JJN3 myeloma cells producing hepatocyte growth factor (HGF) that have been embedded in various types of alginate capsules. Parameters that affect capsule integrity such as homogenous and inhomogenous gel cores and addition of an outer poly-L-lysine (PLL)-alginate coating were evaluated in relation to cell functions. When cells were encapsulated, the PLL layer was found to be absolutely required for the capsule integrity. The JJN3 and 293 endo cells displayed completely different growth and distribution patterns of live and dead cells within the microcapsules, as shown by 3D pictures reconstructed from images taken with confocal laser scanning microscopy (CLSM). Encapsulated JJN3 cells showed a bell-shaped growth and HGF secretion curve over a time period of 5 months. The 293 endo cells reached a plateau phase in growth after 23 days postencapsulation; however, after around 30 days a fraction of the microcapsules started to disintegrate. Microcapsule disintegration occurred with time irrespective of capsule and cell type, showing that alginate microcapsules possessing relatively high gel strength are not strong enough to keep proliferating cells within the microcapsules for prolonged time periods. Although this study shows that the stability of an alginate-based cell factory can be increased by a PLL-alginate coating, further improvement is necessary with regard to capsule integrity as well as controlling the cell growth before this technology can be used for therapy.
INTRODUCTION
recombinant therapeutic proteins have also been tried (1,3,7,27). Installment of microencapsulated cells pro-Transplantation of cells producing therapeutic producing endostatin with the purpose to diminish the teins is a potential strategy for treatment of various disgrowth of gliomas in animal models has been reported eases. Encapsulation of the cells is one way to protect recently (16, 25) . Genetically engineered cells may imthe producer cells from the host immune system, thus prove treatment of a range of different diseases, but so preventing the direct contact with immune cells, cytofar only a few attempts to optimize the alginate microkines, immunoglobulins, and complement factors. The capsules for proliferating cells have been done (4,8, entrapment of cells within spheres of Ca 2+ alginate has 23,34). Because there are different ways of making algibecome a well-established technique. The first report on nate microcapsules, attempts should be made to optisuccessful transplantation in alginate-poly-L-lysine mize these microcapsules for proliferating cells. (PLL) capsules was by Lim and Sun 21 years ago (20) .
Alginates constitute a family of unbranched binary Promising results with transplanted pancreatic islets encopolymers of 1-4 linked β-D-mannuronic acid (M) and capsulated in alginate have been reported both in large α-L-guluronic acid (G). The composition and sequence animal models and in type I diabetic patients (18,31- varies widely depending on the tissue and organism taken 33, 36) . Approaches using proliferating cells delivering from. The functional property of alginate varies with composition. The monomers are arranged in a pattern of MATERIALS AND METHODS blocks along the chain, with homopolymeric regions in Materials the alginate chain (M and G blocks) interspersed with Alginates were prepared from Laminaria hyperborea regions of alternating structures (MG blocks) (30) . Divastipe (UP-LVG, Pronova Biopolymers, Oslo, Norway). lent cations like Ca 2+ bind preferentially to G blocks;
Alginate used for capsule core consisted of 63% α-Lthus, the compositions of the alginates are important for guluronic acid (G) and 37% β-D-mannuronic acid (M) the gel-forming properties. Beads made of alginate with with an average molecular weight of 277 kDa. Outer a G content higher than 70% and an average length of coat consisted of 68% G and 38% M with an average G-blocks of about 15 have the highest mechanical molecular weight of 142 kDa. Chemical compositions strength (30) . Further, increase of the capsule stability is are described by Strand (35) . PLL (Sigma Chemicals, achieved by coating the capsule with a polycation like St. Louis, MO) had a molecular weight of 27.5 kDa. PLL (39) , which also reduces and controls the capsule MTT [3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyl tetrazopermeability (14, 17) . In the original procedure of algilium bromide] was purchased from Sigma and Live/ nate capsule formation, still used with minor changes Dead Viability/Cytotoxicity kit for animal cells from by many groups, the calcium alginate gel core is partly Molecular Probes (Eugene, OR). The murine monodissolved by treating the beads with calcium-sequesterclonal antibodies 3F4 and 2B5 and polyclonal rabbit aning agents. These capsules are less stable than capsules tiserum against human HGF (5) and HGF standards (28) with a solid core (40) . The alginate distribution in a solid were made in our laboratory. core can also be varied by carefully controlling the kinetics of the cross-linking process (29). By forming the Cells and Cultivation gel beads in the absence of a charged osmolyte, the gel The human myeloma cell line JJN3 producing HGF spheres become inhomogeneous with the highest gel (5) was grown in RPMI-1640 (Gibco BRL, Life Techconcentration near the surface (41, 42) . When inhomogenologies, Pailsley, UK) supplemented with 10% fetal neous microcapsules are formed, the higher alginate calf serum (Integro b.v., Holland), 2 mM glutamin, and concentration at the surface results in both reduced po-40 µg/ml gentamycin. The human embryonic kidney rosity at the outer parts of the core and enhanced binding cells (293-EBNA, Invitrogen) expressing Epstein-Barr of PLL at the surface, further reducing the porosity (40) .
virus nuclear antigen (EBNA-1, Invitrogen) transfected The success of alginates as encapsulation material for with the endostatin gene (46) were a gift from Dr. therapeutic cells will rely on an appropriate choice of Bjoern Reino Olsen at Harvard University (Cambridge, materials and methodology for different applications.
MA). The 293 endo cells were grown in RPMI-1640 The use of proliferating cells instead of nonproliferating supplemented with 10% fetal calf serum (Integro b.v, tissue raises new questions regarding cellular growth, Holland), 2 mM glutamin, 100 U/ml penicillin/streptosurvival, and secretion as well as the requirements for mycin, 0.5 µg/ml puromycin (Clontech, Palo Alto, CA), capsule stability. We have addressed these questions by and 250 µg/ml G-418 (Invitrogen). studying the growth, survival, and secretion of therapeu-All cultures with encapsulated cells were fed with tic proteins from two different cell types in four different fresh media every 1-3 days, ensuring good growth conalginate microcapsules. The cell lines studied were the ditions. Capsules were washed through filters (pore size human myeloma cells (JJN3) producing hepatocyte 300 µm) in Hanks balanced salt solution 1640 (HBSS) growth factor (HGF) (5) and the human embryonic kid-(Gibco BRL, Life Technologies) for depletion of free ney cells expressing Epstein-Barr virus nuclear antigen-1 growing cells. (293-EBNA) transfected with the gene for endostatin Immobilization of Cells in Alginate Capsules (293 endo cells) (46). The 293 endo cells are previously reported to diminish the growth of gliomas (25). Micro-Cells (1 × 10 7 ) were suspended in either 0.9% NaCl (for homogeneous capsule formation) or in 0.3 M man-capsules were made of alginate with high guluronic acid content and a gelled core, resulting in a mechanically nitol (inhomogeneous capsule formation) to a final volume of 0.5 ml. The cell solutions were mixed with 4.5 strong capsule. The four microcapsules were made with either a homogeneous or an inhomogeneous core, and ml 2% alginate (sterile filtered with 0.3 M mannitol for inhomogeneous and 0.9% NaCl for homogeneous mi-compared to corresponding microcapsules covered by PLL, further increasing the strength of the capsules. The crocapsules) in a 10-ml syringe to a final concentration of 2 × 10 6 cells/ml and 1.8% alginate. proportion of live and dead cells inside the capsules was studied by use of confocal laser scanner microscopy Ca-alginate beads were formed by letting droplets of alginate/cell solution fall into a solution of CaCl 2 . For (CLSM) and live/dead stain. Three-dimensional images were constructed to study the distribution of live and homogeneous capsule formation a gelling solution of 50 mM CaCl 2 with 0.08 M NaCl was used. For inhomo-dead cells.
geneous capsule formation a solution of 50 mM CaCl 2
EthD-1 and 1 µM Calcein AM) in PBS/medium solution (1:1) for 10-60 min before washing twice in PBS. An and 0.15 M mannitol was used. An electrostatic droplet generator (750 mV) with 0.4-mm needles (two needles argon 488 nm laser was used for excitation of calcein and the emission light between 505 and 530 nm was for JJN3 encapsulation and four needles for 293 endo cell encapsulation), flow stream of 40 ml/h, and 2.2 cm be-detected. An HeNe 543 nm laser was used for excitation of EthD-1 and the emission light over 650 nm detected. tween the needle tip and CaCl 2 solution. Capsules were gelled in CaCl 2 solution for 5 min, or 10 min for encapsu-Green fluorescence is emitted from the intracellular esterase-converted calcein in live cells and red fluores-lated JJN3 cells without PLL. PLL-coated microcapsules were incubated with 0.05% PLL dissolved in 0.9% NaCl cence indicates dead cells. Using a Zeiss 510 Confocal microscope, optical sections through the microcapsules for 10 min, followed by 10 min in 0.1% alginate solution containing either 0.3 M mannitol (inhomogeneous micro-and through equator overlaid transmitted light were taken of the examined capsules. Three-dimensional im-capsules) or 0.15 M NaCl (homogeneous microcapsules). Between each step capsules were quickly washed by a ages were constructed by a 3D program for LSM (Zeiss, version 1.4 1b). The pictures were constructed from sec-flow of 30 ml NaCl. All solutions used were adjusted to pH 7.4 before use. Encapsulated cells were stored in cul-tions through one half of the capsule when cells filled the microcapsules, due to limited passage of the fluores-ture medium in 175-cm 3 flask in 5% CO 2 at 37°C. cence light. The detection of the viability in the central MTT Assay core was also restricted when cells filled the microcap-The viability of encapsulated cells was measured by sules. This resulted in 3D constructions where only the a modification of the MTT assay (22) . Briefly, about cells in the outer parts of the microcapsules were shown. 200 capsules from each condition were taken out, washed
The alginate microcapsules became opaque with time twice in HBSS, conditioned in medium with 0.5 mg/ml when containing JJN3 cells. This affected the ability to MTT for 4 h at 37°C, and washed twice in 0.9% NaCl.
analyze the encapsulated JJN3 cells, and LSM analysis The microcapsules were stored in 0.9% NaCl at 4°C. was impossible after more than 84 days of cultivation. With JJN3 cells, 40 microcapsules in quadruplicate were analyzed by dissolving the formazan crystals by first in-HGF ELISA cubating with 200 µl 10% SDS in 0.01 M HCl for 2. 5 HGF was measured by a Sandwich ELISA as deh at room temperature, then adding 200 µl DMSO for scribed by Seidel et al. (28) . Monoclonal antibodies to 2-h incubation at 37°C. From each vial, 200 µl solution HGF denoted 3F4 and 2B5 were used as catching antiwas transferred to a 96-well plate and optical densities bodies. Capsules were washed and medium conditioned measured at 570 nm in a microplate reader (Novapath TM , with the total fraction of capsules for 20-27 h before Mini Reader). For the capsules containing 293 endo sampling. The amount of HGF (µg/fraction of microcapcells, 400 µl DMSO was added to 40 microcapsules in sules) was given by the equation: volume × concentraquadruplicate and incubated for 2.5 h at room temperation per 24 h. ture. Thereafter a solution of 50 µl of 0.1 M glycine/0.1 M NaCl, pH 10.5, was added and optical density read Detection of Human Endostatin from 200 µl as described before.
Human endostatin was detected by use of the Accu-Cell Viability After Direct Exposure of PLL cyte Human Endostatin kit (Cytimmune Sciences Inc., and CaCl 2 Solutions College Park, MD). Medium (1 ml) was conditioned The cell viability was evaluated following direct exwith 40 alginate microcapsules for 24-28 h. Results are posure to different solutions used for capsule formation.
given as µg endostatin per 40 capsules per day from the Cells (2 × 10 6 ) were incubated with 1 ml 0.05% PLL in mean ± SD of two to four replicates, except for only a 0.9% NaCl, 50 mM CaCl 2 /0.15 M mannitol, 50 mM single value for homogeneous microcapsules at day 29. CaCl 2 /0.9% NaCl, or in medium (control) for 10 min in 15-ml tubes (Sarstedt, Germany). The solutions were Statistics removed by centrifugation (7 min, 1500 rpm), and the A paired sample t-test (two-tailed) was used for meacells added to 2 ml medium. Cells were seeded (50,000suring of differences in survival between control cells 200,000) in 96-well plates with 200 µl medium. Immeand cells exposed with the solutions used for capsule diately and after 24 h in culture the viability was meaformation. Mann-Whitney rank distribution was used for sured with MTT as described by Espevik (12) .
comparing the growth of JJN3 cells in the two types of Confocal Microscopy of Encapsulated Cells microcapsules and for internal comparisons. The differences were considered as significant with a value of p < JJN3 cells and 293 endo cells were precultured in alginate capsules and incubated with diluted dyes (2 µM 0.05. The values are given as the mean ± SD percent survival of the exposed cells compared with the control from 5-9 experiments. The solutions were the same as used in capsule formation with 50 mM CaCl 2 in either 0.15 M mannitol or 0.08 M NaCl. The PLL (0.05%) solution was the same as used for outer coating. n.s.: not significant.
RESULTS

About 10 days after encapsulation of 293 endo cells, the cells penetrated the noncoated microcapsules, forming Effects of Different Encapsulation Procedures
cell clusters at the capsule surface ( Fig. 2D ). These data on Cell Survival clearly demonstrate that alginate microcapsules require The survival of cells 1 day after encapsulation within PLL to keep these cell types encapsulated. different capsules was measured by a modified MTT assay (see Materials and Methods) and by 3D construc-
The Growth of Encapsulated JJN3 Cells and tion of images of encapsulated cells stained with live/ Secretion of HGF dead viability assay (Fig. 1 ). Both PLL coating and con-
The encapsulated JJN3 cells were kept alive in algistruction of inhomogeneous capsules reduced the nate capsules coated with 0.05% PLL for about 5 amount of live JJN3 cells. The 293 endo cells were less months as measured by MTT activity and HGF secretion affected by the encapsulation procedures. Direct expo- (Fig. 3A, B) . Few of the encapsulated JJN3 cells formed sure of PLL was toxic to both cell lines (Table 1) . After multicellular spheroids after encapsulation. This resulted exposure for 10 min the survival was 27 ± 9% for 293 in unequal growth between different microcapsules the endo cells and 15 ± 7% for JJN3 cells (p < 0.05). The first 45 days after entrapment (Fig. 3C ). As shown in impact of the CaCl 2 /NaCl solutions on the viability was the confocal images, only a few cell clusters of various negligible (p > 0.05); however, the CaCl 2 /mannitol comsizes were observed among several dead cells 8 days bination (used for inhomogeneous capsule formation) after entrapment ( Fig. 4) . At day 15, multicellular spherwas slightly toxic for the cells, because the survival was oids consisting mostly of live cells had formed in some decreased compared with the control (p < 0.05).
microcapsules. Within 23 days, the multicellular spher-The Effect of PLL Upon Capsule Integrity oids contained approximately equal amounts of live and dead cells. This proportion between live and dead cells PLL was necessary for capsule integrity in both homogeneous and inhomogeneous capsules and for both seemed to continue till day 84. The growth was significantly higher in the inhomogeneous capsules from 7 cell lines. However, the capsule integrity was affected differently by the two cell types. As soon as 1 day after days after entrapment and until day 134 (Fig. 3A) . The highest viability was measured at day 84 for each cap-encapsulation of JJN3 cells in the absence of a PLL coat, alginate capsules disintegrated and no intact capsules sule type (p < 0.05 internal comparisons); this corresponded with the observation of all microcapsules being were observed (Fig. 2B ). After encapsulation of 293 endo cells, noncoated alginate capsules remained intact.
filled with cells. Broken microcapsules were frequently observed from this stage and throughout the rest of the by the confocal images in Figure 5 . Only a few dead cells were observed 3 days after encapsulation. The cell experiment. After 148 days of encapsulation, the viability was comparable to the first week after encapsulation clusters increased in size for each day, and up to day 10 mostly live cells were detected. At day 20, all microcap-and the study was terminated. The HGF secretion from encapsulated JJN3 cells corresponded well with the cell sules were completely filled up with 293 endo cells (Fig.  3F ), thus reflecting a growth pattern completely differ-growth. The secretion pattern was bell shaped, with the highest secretion detected at day 84 from the inhomoge-ent from the JJN3 cells. The 293 endo cells grew equally well in homogeneous and inhomogeneous alginate cap-neous microcapsules. The highest amount of HGF was detected at day 84 when 8.7 µg/fraction inhomogeneous sules coated with PLL ( Fig. 3D) . A steady state in cell growth was reached between days 13 and 21. Confocal microcapsules and 7.2 µg/ml homogeneous microcapsules were measured. images in this period showed an increased amount of dead cells, especially located to the inner parts of the The Growth of Encapsulated 293 endo Cells capsules. This is illustrated in the confocal picture taken and the Production of Endostatin on day 13 (Fig. 5 ). However, from this stage, the fluo-Most of the 293 endo cells adapted well to the algirescent light detected from the capsule core was renate and formed several multicellular spheroids, as seen duced. A sudden rise in growth was detected by the MTT assay at day 23 (Fig. 3D ). The confocal images at shown and also in Figure 3F where several cells are growing through broken microcapsules (day 42). The al-this stage showed a more or less continuous layer of cells, consisting mostly of live cells, with some dead ginate microcapsules coated with PLL were therefore not mechanically strong enough to keep the highly pro-cells ( Fig. 5 ). A similar distribution was observed at day 35 when the microcapsules were completely filled by liferating 293 endo cells encapsulated under optimal growth conditions. The capsular diameter increased cells. The experiment was terminated at day 42 due to massive breakage of the alginate microcapsules, and not throughout the study, thus reflecting changes in the microcapsules containing 293 endo cells. For micro-because of cell death. This is illustrated in Figure 5 where a broken capsule containing mostly live cells is capsules with PLL the diameter after encapsulation was 586 ± 41 µm (n = 20) for homogeneous and 585 ± 41 µm (n = 20) for inhomogeneous microcapsules (given as middle value ± SD). After 36 days the diameter had increased to 760 ± 50 µm (n = 20) for homogeneous and 721 ± 54 µm (n = 20) for inhomogeneous microcapsules with PLL. The endostatin production was measured by enzyme immunoassay from 1 ml medium conditioned with 40 alginate microcapsules for 24-28 h. As for the growth of the 293 endo cells, the amount of endostatin secreted from the encapsulated 293 endo cells reached a plateau between days 22 and 35. A steady state of endostatin secretion around 0.6-0.7 µg endostatin/40 microcapsules/24 h was established within the inhomogeneous microcapsules. The production of endostatin in homogeneous microcapsules was slightly higher with maximum 0.936 µg/40 microcapsules/24 h at day 29.
DISCUSSION
Our results demonstrate that proliferating cells may survive and proliferate well, following encapsulation in different alginate microcapsules with high gel strength. The different growth patterns between the two cell lines demonstrate that the growth potential inherent to different cell lines is an important determinant for survival in alginate microcapsules. The difference in the cellular growth may be influenced by the sensitivity for rigid matrixes. Solid stress is shown to inhibit the growth of tumor spheroids (15) , and cellular growth has been shown to be inhibited within alginate microcapsules with increasing concentrations of alginate and guluronic acid (8, 34) . This may also explain the fact that the growth of JJN3 cells and secretion of HGF was higher within inhomogeneous microcapsules, because these microcapsules possess less alginate in the center of the capsule core (41) .
Most of the 293 endo cells adapted to the alginate and proliferated well within our microcapsules. Only a few dead cells were observed within the first 10 days after encapsulation. Within 13 days the microcapsules were filled with cells and dead cells appeared. This was also reflected by the MTT viability measurements demonstrating a steady state between days 13 and 21. Cell death may be due to a reduced diffusion of oxygen, nutrients, and waste products. In addition, it is expected that the rate of diffusion decreases with increasing cell numbers. Using JJN3 cells an approximately constant ratio between live and dead cells was observed on the surface of multicellular spheroids between days 23 and 84 postcapsulation. The balance between live and dead cells may be distorted by the accumulation of dead cell components, which increases with time. The accumulation of waste products may also reduce the access of oxygen and nutrition to the growing cells. For such reasons, the functional time for microcapsules containing proliferating cells is limited, as demonstrated by the growth curve of the encapsulated JJN3 cells. The continuous cell proliferation and change in rate of protein secretion make it difficult to determine an exact dosage of therapeutic proteins. Control or hindrance of the cellular growth is therefore needed. Increasing the gel strength may partly achieve this. However, it is our opinion that the cellular growth also needs to be controlled on the cellular level. One way to control cellular growth and also the secretion rate is described by Mazur et al. (21) . Cells were transfected with a multicistronic expression unit encoding the product gene and a cytostatic cell cycle-arresting gene under control of a tetracyclinerepressible (tet off ) promoter (21) . By the addition of tetracycline the cells were in a nonproductive growth phase, while removing the tetracycline lead to a proliferation-inhibited production phase. By such systems it is possible to keep the cells in a nonproliferating production phase following transplantation, without any external control of the cellular growth. To ensure free passage of nutrition, oxygen, and waste products, the cell proliferation should be inhibited when only small spheroids are present. Short cultivation time may also limit the amount of dead cells within microcapsules, thus reducing inflammatory reactions that may be caused from the release of components from dead cells (2). An important consideration is also that our experiments were performed with nutritional excess; thus, these studies show the cell growth under approximately optimal conditions. In an in vivo situation there may be nutrition scarcity and host reactions towards the cells, which may reduce the growth rate and cell growth rate may be tion of proliferation at an early growth stage is likely to prolong the time period when the microcapsules are slower than seen in our experiment.
Our study showed that optimizing the capsule intact. Alginate microcapsules are shown to have advantages strength by making microcapsules with high G contents, gelled cores, and inhomogeneous distribution was not among other encapsulation devices (19) . However, the structural stability of the microcapsules needs to be im-sufficient for keeping proliferating cells encapsulated over time. Addition of PLL was necessary to improve proved for proliferating cells. Further stabilizing can be achieved using barium ions (40, 47) and by increasing the structural stability and to act as a mechanical barrier. The reason for the early breakage of microcapsules in the PLL layer (39) . However, PLL is involved in the fibrotic reactions against empty alginate microcapsules the absence of PLL when containing JJN3 cells is not understood. Alginate is a substrate for enzymes with en- (9, 35) . It is therefore important to reduce this layer as much as possible. Alternatively, it could be replaced by dolyase activity (37) . Heparanases with endoglycosidase activity are found in cancerous cells, and are suggested chitosan (6, 24) . Chitosan, a biopolymer comprising 1-4 linked N-acetylglucosamin residues, makes a stronger as part of the metastatic mechanisms for tumor progress in general (44). One possible explanation for the ob-complex with alginate than PLL because the distance between the charges is approximately the same for the served capsule breakage may be that enzymes with endolyase activity such as heparanases are present in the two molecules (13) . With a pKa value of about 6, the solubility of chitosan at physiological pH might pose a JJN3 myeloma cells, but so far no experiments have been performed to verify this. problem. However, as shown here with the JJN3 cells, only a few cells have to survive the encapsulation proce-The penetration of 293 endo cells through noncoated alginate microcapsules showed that these cells required dure to establish a functional cell reactor. Proliferating cells may therefore need less gentle encapsulation proce-a stronger barrier. Penetration of cells is also described by others using noncoated alginate microcapsules (38) , dures compared with nonproliferating tissue. Another approach to increase the bioreactor function is to im-and the presence of PLL was previously shown to improve the long-term structural integrity (4). However, prove the capsule materials. A combination of sodium alginate, cellulose sulfate, and polymethylene-co-gua-alginate-PLL-alginate microcapsules failed to keep the proliferating cells encapsulated more than about 30 nine has shown promise according to stability and biocompatibility (45). In our laboratory a range of alginate days. Two different mechanisms are probably involved in this. First, phosphate, a constituent of the culture me-modifying enzymes has recently been identified, sequenced, and cloned. These are the mannuronan C-5 dia, has higher affinity for Ca 2+ than alginate. Changing of culture media may lead to continuous leakage of Ca 2+ epimerases, which have the capacity to convert mannuronic acid into guluronic acid residues in the polymer and therefore softening of the gel. Second, cell proliferation postencapsulation may pose a burden to the struc-chain (11) . By controlling the composition and the sequential distribution of monomers, polymers with im-tural integrity of the alginate microcapsules, as alginate free areas around the cells and open holes containing proved gelling properties can be made (10) . We have indications that the modification of the alginate will cell debris have been described (26) . Also, encapsulation of cells is shown to decrease the capsule stability com-make it possible to create a more stable gel core. By combining these new alginates with other approaches for pared with empty microcapsules (43) . Destabilization of the alginate microcapsule gel network may also explain gel strengthening, it may be possible to make an alginate capsule strong enough to keep proliferating cells within the sudden rise in the growth rate of the 293 endo cells 23 days after encapsulation. There is a possibility that the capsule over longer time periods. the capsule cores at this stage consisted mostly of cells
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